Literature DB >> 30604042

Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater.

Min Hwan Kim1,2, Mi Jang3, Hoguen Kim3, Woo Jung Lee4, Chang Moo Kang5,6, Hye Jin Choi7,8.   

Abstract

Adenocarcinoma of the ampulla of Vater (AOV) is classified into intestinal type (IT) and pancreatobiliary type (PB); however, the immunological properties of these subtypes remain to be characterized. Here, we evaluated the clinical implications of PD-L1 expression and CD8+ T lymphocyte density in adenocarcinomas of the AOV and their potential association with Yes-associated protein (YAP). We analyzed 123 adenocarcinoma-of-the-AOV patients who underwent surgical resection, and tumors were classified into IT or PB type. Tumor or inflammatory cell PD-L1 expression, CD8+ T lymphocyte density in the cancer cell nest (intratumoral) or in the adjacent stroma, and YAP localization and intensity were analyzed using immunohistochemical staining. PB-type tumors showed higher tumoral PD-L1 expression than IT-type tumors, and tumoral PD-L1 expression was associated with a shorter disease-free survival (DFS) [hazard ratio (HR), 1.77; p = 0.045] and overall survival (OS) (HR 1.99; p = 0.030). Intratumoral CD8+ T lymphocyte density was higher in IT type than in PB type and was associated with a favorable DFS (HR 0.47; p = 0.022). The nuclear staining pattern of YAP in tumor cells, compared to non-nuclear staining patterns, was more frequently associated with PB type and increased tumoral PD-L1 expression. Nuclear YAP staining was a significant prognostic factor for OS (HR 2.21; p = 0.022). These results show that the two subtypes of adenocarcinoma of the AOV exhibit significant differences in tumoral PD-L1 expression and intratumoral CD8+ T lymphocyte density, which might contribute to their distinct clinical features.

Entities:  

Keywords:  Adenocarcinoma of the ampulla of Vater; CD8 T lymphocytes; Immunohistochemistry; PD-L1; Prognosis; YAP

Mesh:

Substances:

Year:  2019        PMID: 30604042     DOI: 10.1007/s00262-018-02293-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  2 in total

Review 1.  Adjuvant therapy for periampullary carcinoma and the significance of histopathological typing: A systematic review.

Authors:  Zhiqing Duan; Yinuo Zhang; Yajie Tang; Ruqing Gao; Jing Bao; Bo Liang
Journal:  Transl Oncol       Date:  2022-04-06       Impact factor: 4.243

2.  Remission from the 5-Fu-Based Chemotherapy to Gemcitabine-Based Chemotherapy-Based on the Pathological Classification of Periampullary Carcinoma: A Case Report and Literature Review.

Authors:  Wei Hu; Zhiqing Duan; Yinuo Zhang; Jing Liu; Jing Bao; Ruqing Gao; Yajie Tang; Tiande Liu; Hu Xiong; Wen Li; Xiaowei Fu; Shousheng Liao; Lu Fang; Bo Liang
Journal:  Onco Targets Ther       Date:  2022-08-25       Impact factor: 4.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.